These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Pharmacological studies on experimental nephritic rats. (4) Improvement of hyperlipemic models in rats utilizing anti-rat kidney rabbit serum and effects of anti-hyperlipemic agents on serum lipid levels.
    Author: Suzuki Y, Honda Y, Ito M.
    Journal: Jpn J Pharmacol; 1978 Oct; 28(5):729-38. PubMed ID: 723001.
    Abstract:
    Three hyperlipemic models in rats were compared regarding serum lipid levels and known anti-hyperlipemic agents were tested for their effects on the hyperlipemia. In rats fed a cholesterol diet (group A), only serum cholesterol level resulted in a marked increase as compared with normal level. In animals given a large dose (0.7 ml/100 g body weight, i.v.) of anti-kidney serum (group B), extremely high elevations of serum total lipid, phospholipid, triglyceride and cholesterol levels were observed. In animals given a small dose (0.3 ml/100 g body weight, i.v.) of anti-kidney serum and fed the cholesterol diet (group C), elevations of these serum lipids except for triglyceride were not only greater than in group B, but also synergistic. On the contrary, serum triglyceride level and proteinuria were less in group C than in group B. Furazabol, clofibrate the beta-sitosterol given orally for 7 days at doses of 1,100 and 500 mg/kg/day, respectively were clearly effective on the hyperlipemia of group C, without affecting the proteinuria. Furthermore, this model was more sensitive to these anti-hyperlipemic agents than groups A and B. From the above results, group C would seem to be an adequate and effective experimental hyperlipemic model.
    [Abstract] [Full Text] [Related] [New Search]